UNSPSC 51261601: Phenoxybenzamine

This classification denotes a carcinogenic aromatic amine and alpha-adrenergic blocking agent with the molecular formula C18H22ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0TTZ664R7Z, chemically known as n-(2-chloroethyl)-n-(1-methyl-2-phenoxyethyl)benzylamine, hydrochloride but generally known as phenoxybenzamine, which bears US NIH Compound Identifier 4768. European Medicines Agency schedules Phenoxybenzamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09778MIG.

UNSPSC 51261601 Phenoxybenzamine is a Commodity code nominally covering a specific pharmaceutical compound, but the recent state and local opportunities posted under it diverge sharply from that narrow scope. Seminole County, Florida's IFB 60459723LAS solicits naloxone and safe drug deactivation systems for community health initiatives—products unrelated to phenoxybenzamine—while the Texas Health and Human Services Commission's RFI HHS0017013 seeks vendor capabilities for direct-to-manufacturer prescription programs without naming phenoxybenzamine or any specific active pharmaceutical ingredient. The code shows little relevant recent activity aligned with its nominal pharmaceutical scope; the two posted opportunities appear to be misclassified under this code or represent broader pharmacy procurement bundling rather than phenoxybenzamine-specific purchasing.

The issuing bodies include county health departments and state health and human services commissions, reflecting public health and pharmacy benefit administration. Geographic activity is limited to Florida and Texas based on recent postings, with no indication of broader or repeat purchasing patterns under this code. Seminole County's solicitation (posted June 30, 2026, with a response deadline of July 26, 2023—a date inconsistency in the source) calls for annual procurement of 1,900 naloxone units and 800 deactivation systems with quarterly deliveries, fixed-fee pricing, and a two-year initial term with one-year renewal option. The Texas RFI (posted April 3, 2026) is exploratory market intelligence gathering with no award value, budget range, or formal evaluation criteria, designed to inform future formal procurement strategy rather than to award a contract. Neither opportunity specifies set-aside designations or emphasizes phenoxybenzamine demand, limiting the code's relevance for vendors focused on this particular pharmaceutical product.